Sign up to access all valuation multiples
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities including MRIs, CT scans, PET scans, X-rays, ultrasounds, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated from the Outpatient segment, which generates revenue by performing imaging studies and providing radiologists’ interpretations of those studies.
2025
5.0K+
Last FY Revenue $949M
Last FY EBITDA $114M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Lumexa Imaging Holdings reported revenue of $949M and EBITDA of $114M.
Lumexa Imaging Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lumexa Imaging Holdings valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $949M | XXX | XXX | XXX |
| Gross Profit | XXX | $96.3M | XXX | XXX | XXX |
| Gross Margin | XXX | 10% | XXX | XXX | XXX |
| EBITDA | XXX | $114M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 12% | XXX | XXX | XXX |
| EBIT | XXX | -$16.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -2% | XXX | XXX | XXX |
| Net Profit | XXX | -$94.1M | XXX | XXX | XXX |
| Net Margin | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | $1.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lumexa Imaging Holdings has current market cap of $1.7B, and EV of $3.0B.
As of December 30, 2025, Lumexa Imaging Holdings's stock price is $18.
See Lumexa Imaging Holdings trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $1.7B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialLumexa Imaging Holdings's trades at 3.2x EV/Revenue multiple, and 26.5x EV/EBITDA.
See valuation multiples for Lumexa Imaging Holdings and 15K+ public compsAs of December 30, 2025, Lumexa Imaging Holdings has market cap of $1.7B and EV of $3.0B.
Equity research analysts estimate Lumexa Imaging Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lumexa Imaging Holdings's P/E ratio is not available.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 26.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -185.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -18.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 233.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLumexa Imaging Holdings's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $22K for the same period.
Lumexa Imaging Holdings's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lumexa Imaging Holdings's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lumexa Imaging Holdings and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $22K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lumexa Imaging Holdings acquired XXX companies to date.
Last acquisition by Lumexa Imaging Holdings was XXXXXXXX, XXXXX XXXXX XXXXXX . Lumexa Imaging Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Lumexa Imaging Holdings founded? | Lumexa Imaging Holdings was founded in 2025. |
| Where is Lumexa Imaging Holdings headquartered? | Lumexa Imaging Holdings is headquartered in United States of America. |
| How many employees does Lumexa Imaging Holdings have? | As of today, Lumexa Imaging Holdings has 5.0K+ employees. |
| Who is the CEO of Lumexa Imaging Holdings? | Lumexa Imaging Holdings's CEO is Ms. Caitlin Zulla. |
| Is Lumexa Imaging Holdings publicy listed? | Yes, Lumexa Imaging Holdings is a public company listed on NAS. |
| What is the stock symbol of Lumexa Imaging Holdings? | Lumexa Imaging Holdings trades under LMRI ticker. |
| When did Lumexa Imaging Holdings go public? | Lumexa Imaging Holdings went public in 2025. |
| Who are competitors of Lumexa Imaging Holdings? | Similar companies to Lumexa Imaging Holdings include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Lumexa Imaging Holdings? | Lumexa Imaging Holdings's current market cap is $1.7B |
| Is Lumexa Imaging Holdings profitable? | Yes, Lumexa Imaging Holdings is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
